Neuroscience Today—February 4, 2026

This week’s Neuroscience update summarizes key developments in clinical progress, regulatory actions, data releases, and strategic partnerships across the field. Highlights include significant clinical trial results and regulatory milestones that may shape future treatment options.

In Today’s Newsletter

Dive deeper

🧪 Sanofi’s venglustat achieves positive Phase 3 results for Type 3 Gaucher disease (GD3) [1] [France • 2 Feb 2026]

https://www.sanofi.com/en/media-room/press-releases/2026/2026-02-02-06-00-00-3229947
Context: LEAP2MONO Phase 3 study shows venglustat improves neurological symptoms in GD3, with plans for regulatory submissions.
Key Point: Venglustat met all primary endpoints and three out of four key secondary endpoints, showing superiority over enzyme replacement therapy (ERT) for neurological outcomes.
Implication: Pivotal treatment for GD3 with neurological manifestations, potentially shifting clinical practices and future treatment landscapes.

💊 Otsuka’s Centanafadine NDA accepted for ADHD [2] [US • 27 Jan 2026]

https://www.otsuka.co.jp/en/company/newsreleases/2026/20260127_1.html
Context: Centanafadine, a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor, has been accepted by the FDA for priority review.
Key Point: Target PDUFA date of July 24, 2026, for ADHD treatment in children, adolescents, and adults.
Implication: Centanafadine could become an important new therapeutic option for ADHD, with potential to expand treatment options for diverse patient populations.

🧠 AbbVie launches Love in Mind™ to highlight the emotional impact of migraines [3] [US • 29 Jan 2026]

https://news.abbvie.com/2026-01-29-AbbVie-Launches-Love-in-Mind-TM-to-Spotlight-the-Emotional-Impact-of-Migraine-on-Romantic-Relationships
Context: Love in Mind™ initiative aims to raise awareness about how migraines affect romantic relationships, based on new survey data.
Key Point: Survey reveals how migraines disrupt dating, intimacy, and emotional well-being, emphasizing the need for holistic care approaches.
Implication: Opening conversations on the emotional toll of migraines may lead to more comprehensive care plans and improve patients’ quality of life.

☢️ Lundbeck presents INFUSE study data on Vyepti® for migraine [4] [Denmark • 30 Jan 2026]

https://news.cision.com/h–lundbeck-a-s/r/lundbeck-presents-new-real-world-data-highlighting-meaningful-improvements-in-patients-severely-impa,c4298837
Context: The INFUSE study demonstrates significant reduction in migraine frequency in patients previously failing anti-CGRP treatments.
Key Point: 75.7% of patients reported improvement in migraine status after two infusions of Vyepti®.
Implication: This real-world evidence further strengthens the case for early intervention with Vyepti® in chronic migraine patients.

💡 Teva & Novartis announce strategic partnership for Mayzent® relaunch in Canada [5] [Canada • 2 Feb 2026]

https://www.biospace.com/press-releases/teva-canada-announces-strategic-partnership-with-novartis-canada-to-relaunch-mayzent-for-multiple-sclerosis-patients-in-canada
Context: Teva takes over exclusive responsibility for the promotion and commercialization of Mayzent® for secondary progressive multiple sclerosis (SPMS) in Canada.
Key Point: This partnership aims to enhance access to Mayzent® for Canadian MS patients with active disease.
Implication: Improved access to this oral therapy for SPMS may contribute to better outcomes for patients struggling with limited treatment options.

🧬 Vect-Horus and OliX Pharmaceuticals form collaboration on siRNA delivery for CNS disorders [6] [France & South Korea • 3 Feb 2026]

https://www.globenewswire.com/news-release/2026/02/03/3230746/0/en/Vect-Horus-Enters-a-CNS-Focused-Research-Collaboration-with-OliX-Pharmaceuticals.html
Context: Collaboration aims to leverage Vect-Horus’ BBB shuttle technology for siRNA delivery across the blood-brain barrier in CNS disorders.
Key Point: Evaluation of delivery efficiency, gene silencing, and biodistribution to advance siRNA-based treatments for CNS diseases.
Implication: Advances in gene delivery for CNS disorders could unlock new treatment avenues for conditions previously inaccessible to traditional therapies.

🧬 GenixCure shifts focus to next-gen AAV vector platform for CNS and rare diseases [7] [South Korea • 2 Feb 2026]

https://www.01net.it/seqster-announces-expanded-partnership-with-praxis-precision-medicines-to-accelerate-clinical-trials-in-cns-disorders/
Context: GenixCure pivots to a next-generation AAV platform, improving CNS-targeting and efficiency for gene therapy in rare diseases.
Key Point: AAV vectors engineered using AI-driven technology, demonstrating significant improvements in CNS targeting, with applications for rare neurological diseases.
Implication: Enhancing AAV vectors’ efficiency could lead to breakthroughs in gene therapies for conditions like Alzheimer’s, ALS, and spinal muscular atrophy (SMA).

💻 SEQSTER & Praxis expand partnership for clinical trials in CNS disorders [8] [US • 2 Feb 2026]

https://www.01net.it/seqster-announces-expanded-partnership-with-praxis-precision-medicines-to-accelerate-clinical-trials-in-cns-disorders/
Context: Expanded partnership focuses on using real-world data (RWD) to improve clinical trial execution and accelerate data collection for CNS treatments.
Key Point: Leveraging RWD for patient recruitment and tracking in clinical trials, including studies on epilepsy treatments.
Implication: Real-world evidence could play a pivotal role in shaping the future of clinical trials and accelerating drug development in the CNS space.

🧘‍♀️ Apollo Neuroscience releases 2025 Year in Review with major milestones [9] [US • 30 Jan 2026]

https://www.prnewswire.com/news-releases/apollo-neuroscience-announces-2025-year-in-review-302675525.html
Context: Apollo’s 2025 data highlights success in improving sleep and reducing stress through its wearable technology, achieving over 143 million extra sleep minutes.
Key Point: SmartVibes AI, an AI-driven system, provides automatic sleep interventions, showcasing significant improvements in sleep continuity.
Implication: Non-invasive interventions for sleep and stress could have broad implications for overall well-being, mental health, and chronic conditions management.

Why it matters

Venglustat could reshape the treatment paradigm for Type 3 Gaucher disease, offering a new hope for patients with neurological involvement.
Centanafadine’s potential approval brings an innovative ADHD treatment option, expanding prescriber choices.
AbbVie’s migraine initiative highlights the complex emotional aspects of migraine management, encouraging a more holistic approach to care.
Lundbeck’s Vyepti® data strengthens its position as a crucial treatment for patients who have failed other migraine therapies.
Teva & Novartis’ partnership enhances the reach and availability of Mayzent® in Canada, addressing unmet needs in SPMS.
Vect-Horus & OliX Pharmaceuticals collaboration may enable breakthrough advancements in RNA-based treatments for CNS disorders.
GenixCure’s next-gen AAV platform offers the potential to revolutionize gene therapies for rare CNS diseases.
SEQSTER & Praxis Precision Medicines are making strides in accelerating clinical trials with real-world data.
Apollo Neuroscience’s advancements in sleep and stress management underscore the value of non-pharmaceutical approaches for mental health.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

📚 View the full Neuroscience archive on our research hub page.

FAQ

What is venglustat and how is it being tested?

Venglustat is a VMAT2 inhibitor being tested in a Phase 3 study for Type 3 Gaucher disease, showing improvements in neurological symptoms compared to enzyme replacement therapy [1].

When is Centanafadine expected to be reviewed by the FDA?

The FDA has set a target action date of July 24, 2026, for the review of Centanafadine’s New Drug Application (NDA) for ADHD [2].

What does Love in Mind™ aim to achieve?

AbbVie’s Love in Mind™ initiative aims to raise awareness about the emotional impact of migraines, particularly on romantic relationships, based on new survey findings [3].

What is the INFUSE study’s impact on Vyepti®?

The INFUSE study data showed that Vyepti® (eptinezumab) significantly reduced migraine frequency in patients who had previously failed other treatments, making it a promising option for chronic migraine patients [4].

What does the Teva-Novartis partnership mean for Canadian MS patients?

The partnership ensures continued access to Mayzent® (siponimod) for Canadian patients with secondary progressive multiple sclerosis (SPMS), expanding treatment availability [5].

How are Vect-Horus & OliX Pharmaceuticals contributing to RNA-based treatments for CNS disorders?

Their collaboration aims to improve siRNA delivery across the blood-brain barrier (BBB), which could unlock new treatment options for CNS disorders [6].

What advances has GenixCure made in gene therapy for CNS disorders?

GenixCure’s next-generation AAV vectors show promising improvements in targeting the CNS, which could revolutionize gene therapies for rare diseases [7].

What role does real-world data play in clinical trials for CNS disorders?

SEQSTER & Praxis Precision Medicines use RWD to enhance clinical trial execution, patient recruitment, and data collection, potentially speeding up CNS drug development [8].

How is Apollo Neuroscience improving sleep and stress management?

Apollo’s wearable technology, powered by SmartVibes AI, has helped users achieve better sleep continuity and stress reduction, with millions of extra sleep minutes reported [9].

Entities / Keywords

Sanofi; venglustat; Type 3 Gaucher disease; neurological manifestations; regulatory submission
Otsuka; Centanafadine; ADHD; FDA; priority review
AbbVie; Love in Mind™; migraine; romantic relationships; survey
Lundbeck; Vyepti®; migraine; real-world evidence; INFUSE study
Teva; Novartis; Mayzent®; multiple sclerosis; Canada
Vect-Horus; OliX Pharmaceuticals; siRNA; blood-brain barrier; CNS disorders
GenixCure; AAV vectors; CNS-targeting; rare diseases
SEQSTER; Praxis Precision Medicines; real-world data; CNS disorders; clinical trials
Apollo Neuroscience; SmartVibes AI; sleep; stress; wearable technology